Janney Montgomery Scott LLC Acquires 5,881 Shares of DexCom, Inc. (NASDAQ:DXCM)

Janney Montgomery Scott LLC grew its stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 2.5% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 238,424 shares of the medical device company's stock after purchasing an additional 5,881 shares during the quarter. Janney Montgomery Scott LLC owned approximately 0.06% of DexCom worth $16,282,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the stock. Forvis Mazars Wealth Advisors LLC raised its holdings in shares of DexCom by 0.7% during the fourth quarter. Forvis Mazars Wealth Advisors LLC now owns 17,481 shares of the medical device company's stock valued at $1,359,000 after acquiring an additional 118 shares in the last quarter. Principal Securities Inc. raised its holdings in shares of DexCom by 3.4% during the fourth quarter. Principal Securities Inc. now owns 4,069 shares of the medical device company's stock valued at $316,000 after acquiring an additional 135 shares in the last quarter. Larson Financial Group LLC raised its holdings in shares of DexCom by 40.5% during the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock valued at $37,000 after acquiring an additional 137 shares in the last quarter. Nia Impact Advisors LLC raised its holdings in shares of DexCom by 1.4% during the fourth quarter. Nia Impact Advisors LLC now owns 9,850 shares of the medical device company's stock valued at $766,000 after acquiring an additional 140 shares in the last quarter. Finally, Level Four Advisory Services LLC raised its holdings in shares of DexCom by 1.1% during the fourth quarter. Level Four Advisory Services LLC now owns 13,196 shares of the medical device company's stock valued at $1,026,000 after acquiring an additional 150 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on DXCM shares. The Goldman Sachs Group started coverage on DexCom in a report on Friday, May 30th. They set a "buy" rating and a $104.00 target price for the company. Cfra Research upgraded DexCom to a "hold" rating in a report on Friday, March 21st. Canaccord Genuity Group upped their target price on DexCom from $103.00 to $106.00 and gave the company a "buy" rating in a report on Friday, May 2nd. Robert W. Baird decreased their price objective on DexCom from $115.00 to $105.00 and set an "outperform" rating for the company in a report on Friday, May 2nd. Finally, Mizuho started coverage on DexCom in a report on Thursday, April 10th. They issued an "outperform" rating and a $85.00 price objective for the company. Four investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, DexCom has an average rating of "Moderate Buy" and an average price target of $98.50.

DexCom Stock Down 1.2%

Shares of DXCM traded down $1.01 during trading hours on Friday, hitting $80.00. The company had a trading volume of 5,238,495 shares, compared to its average volume of 4,367,603. The firm has a fifty day moving average price of $79.80 and a 200-day moving average price of $79.40. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.32 and a current ratio of 1.50. The stock has a market capitalization of $31.37 billion, a price-to-earnings ratio of 59.70, a P/E/G ratio of 1.73 and a beta of 1.46. DexCom, Inc. has a 52-week low of $57.52 and a 52-week high of $117.27.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.01). The company had revenue of $1.04 billion during the quarter, compared to analysts' expectations of $1.02 billion. DexCom had a return on equity of 30.05% and a net margin of 12.90%. DexCom's revenue for the quarter was up 12.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.32 EPS. On average, equities research analysts forecast that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insider Transactions at DexCom

In other DexCom news, Director Nicholas Augustinos sold 3,672 shares of DexCom stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $82.80, for a total value of $304,041.60. Following the completion of the sale, the director now owns 33,411 shares of the company's stock, valued at approximately $2,766,430.80. The trade was a 9.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Mark G. Foletta sold 2,750 shares of the stock in a transaction on Monday, June 16th. The shares were sold at an average price of $83.13, for a total value of $228,607.50. Following the transaction, the director now directly owns 56,621 shares in the company, valued at $4,706,903.73. The trade was a 4.63% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 25,724 shares of company stock valued at $2,157,034 in the last quarter. 0.32% of the stock is owned by insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.